REGN Stock Analysis: Regeneron Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 75.652m USD | 12M Return: 31.7% | US75886F1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 534M
EPS Trend: 55.9%
Qual. Beats: 1
Rev. Trend: 95.6%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a U.S. biopharmaceutical company founded in 1988 and headquartered in Tarrytown, New York. The company operates across the full pharmaceutical value chain, discovering, developing, manufacturing, and commercializing treatments for a broad range of conditions such as eye diseases, allergic and inflammatory disorders, cardiovascular and metabolic diseases, neurological conditions, infectious diseases, rare diseases, and cancer.
The companys commercialized portfolio includes EYLEA (an anti-VEGF therapy widely used for retinal diseases), Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for high cholesterol, and Kevzara for rheumatoid arthritis. As a biotechnology company, Regeneron invests heavily in research and development and relies on a pipeline of internally discovered and externally partnered product candidates to sustain long-term growth.
Regeneron pursues an extensive partnership strategy, collaborating with companies such as Bayer (EYLEA), Alnylam (RNAi therapeutics), Intellia (CRISPR/Cas9 gene editing), Hansoh (GLP-1/GIP receptor agonist), Tessera (gene editing for Alpha-1 antitrypsin deficiency), Telix (radiopharmaceuticals), and CytomX (conditionally-activated bispecific cancer therapies). Such licensing and collaboration agreements are a common feature of the biotech sector, allowing companies to share development costs, access complementary technologies, and extend geographic reach for both approved products and early-stage candidates.
- EYLEA sales pressured by Vabysmo competition and biosimilar threat
- Dupixent revenue growth accelerates across new label expansions
- Obesity pipeline entry via Hansoh HS-20094 GLP-1/GIP deal
| Net Income: 4.33b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.62 > 1.0 |
| NWC/Revenue: 83.14% < 20% (prev 92.81%; Δ -9.67% < -1%) |
| CFO/TA 0.11 > 3% & CFO 4.44b > Net Income 4.33b |
| Net Debt (-5.29b) to EBITDA (5.75b): -0.92 < 3 |
| Current Ratio: 3.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (106.8m) vs 12m ago -1.66% < -2% |
| Gross Margin: 84.86% > 18% (prev 85.57%; Δ -0.71% > 0.5%) |
| Asset Turnover: 38.86% > 50% (prev 37.19%; Δ 1.67% > 0%) |
| Interest Coverage Ratio: 94.25 > 6 (EBIT TTM 5.22b / Interest Expense TTM 55.4m) |
| A: 0.31 (Total Current Assets 18.4b - Total Current Liabilities 5.53b) / Total Assets 41.7b |
| B: 0.90 (Retained Earnings 37.6b / Total Assets 41.7b) |
| C: 0.13 (EBIT TTM 5.22b / Avg Total Assets 40.0b) |
| D: 3.17 (Book Value of Equity 31.7b / Total Liabilities 10.0b) |
| Altman-Z'' = 9.17 = AAA |
| DSRI: 1.07 (Receivables 6.57b/5.61b, Revenue 15.5b/14.2b) |
| GMI: 1.01 (GM 85.57% / 84.86%) |
| AQI: 0.99 (AQ_t 0.43 / AQ_t-1 0.43) |
| SGI: 1.09 (Revenue 15.5b / 14.2b) |
| TATA: -0.00 (NI 4.33b - CFO 4.44b) / TA 41.7b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 746.54 with a total of 466,002 shares traded. Over the past week, the price has changed by +1.54%, over one month by -7.57%, over three months by +11.90% and over the past year by +31.67%.
Current recommended Stop Loss: 719.70 (which is 3.6% or 1.3 ATR below the current price).
Regeneron Pharmaceuticals has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy REGN.
- StrongBuy: 14
- Buy: 4
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 853.2 | 14.3% |
P/E Trailing = 18.7595
P/E Forward = 14.5138
P/S = 4.8699
P/B = 2.6032
P/EG = 1.3196
Revenue TTM = 15.5b USD
EBIT TTM = 5.22b USD
EBITDA TTM = 5.75b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last fiscal year)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 720.0m
Net Debt = -5.29b USD (calculated: Debt 2.71b - CCE 7.99b)
Enterprise Value = 70.4b USD (75.7b + Debt 2.71b - CCE 7.99b)
Interest Coverage Ratio = 94.25 (Ebit TTM 5.22b / Interest Expense TTM 55.4m)
EV/FCF = 19.98x (Enterprise Value 70.4b / FCF TTM 3.52b)
FCF Yield = 5.01% (FCF TTM 3.52b / Enterprise Value 70.4b)
FCF Margin = 22.67% (FCF TTM 3.52b / Revenue TTM 15.5b)
Net Margin = 27.86% (Net Income TTM 4.33b / Revenue TTM 15.5b)
Gross Margin = 84.86% ((Revenue TTM 15.5b - Cost of Revenue TTM 2.35b) / Revenue TTM)
Gross Margin QoQ = 86.56% (prev 81.43%)
Tobins Q-Ratio = 1.69 (Enterprise Value 70.4b / Total Assets 41.7b)
Interest Expense / Debt = 2.05% (Interest Expense 55.4m / Debt 2.71b)
Taxrate = 16.21% (837.3m / 5.17b)
NOPAT = 4.38b (EBIT 5.22b * (1 - 16.21%))
Current Ratio = 3.34 (Total Current Assets 18.4b / Total Current Liabilities 5.53b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 31.7b)
Debt / EBITDA = -0.92 (Net Debt -5.29b / EBITDA 5.75b)
Debt / FCF = -1.50 (Net Debt -5.29b / FCF TTM 3.52b)
Total Stockholder Equity = 31.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.83% (Net Income 4.33b / Total Assets 41.7b)
RoE = 13.81% (Net Income TTM 4.33b / Total Stockholder Equity 31.3b)
RoCE = 15.67% (EBIT 5.22b / Capital Employed (Equity 31.3b + L.T.Debt 1.99b))
RoIC = 12.34% (NOPAT 4.38b / Invested Capital 35.5b)
WACC = 7.99% (E(75.7b)/V(78.4b) * Re(8.21%) + D(2.71b)/V(78.4b) * Rd(2.05%) * (1-Tc(0.16)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.18 | Cagr: -3.27%
[DCF] Terminal Value 74.22% ; FCFF base≈3.65b ; Y1≈3.41b ; Y5≈3.12b
[DCF] Fair Price = 539.8 (EV 49.3b - Net Debt -5.29b = Equity 54.6b / Shares 101.1m; r=8.35% [WACC [floored]]; 5y FCF grow -8.39% → 2.50% )
EPS Correlation: 55.92 | EPS CAGR: 1.10% | SUE: 3.13 | # QB: 1
Revenue Correlation: 95.59 | Revenue CAGR: 5.78% | SUE: 2.76 | # QB: 1
EPS current Quarter (2026-09-30): EPS=16.02 | Chg30d=+0.11% | Revisions=+87% | Analysts=20
EPS current Year (2026-12-31): EPS=54.80 | Chg30d=+2.33% | Revisions=+88% | GrowthEPS=+23.7% | GrowthRev=+18.6%
EPS next Year (2027-12-31): EPS=50.63 | Chg30d=+0.48% | Revisions=+18% | GrowthEPS=+15.4% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +83% (up=48, down=3)